Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet
By Ben Glickman
Intel released restated results for the last three years to break out its foundry business, revealing the segment generated an operating loss of about $7 billion in 2023. The business's sales from other parts of Intel, or internal revenue, fell sharply to $18 billion that same year. Shares fell 3.8%, to $42.26, after hours.
Vanda Pharmaceuticals said it had received regulatory approval for Fanapt to treat manic or mixed episodes linked to bipolar I disorder in adults. The treatment has been used in adults with schizophrenia for years, but the company said the new indication would increase Fanapt's commercial opportunity. Shares surged 31%, to $5.13, in late trading.
OneMedNet said it had secured up to $4.54 million in cash through a securities purchase agreement with an institutional investor. The company also announced Aaron Green as its next chief executive as predecessor Paul Casey retires. Shares rose 44%, to $1.14, in the post-market session.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 02, 2024 19:54 ET (23:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?